AdvertisementAd feedback
Smiling nurse prepares to vaccinate an older man in a home setting.

Is Moderna’s Cancer Vaccine a Game Changer for the Stock?

+ Retirely on ›
Image source: Getty Images.
Advertisement

Key Points

  • Intismeran and Keytruda have demonstrated in clinical trials that they can drastically improve outcomes for melanoma patients.

  • The combined treatment has reduced the risk of death and melanoma spreading or returning.

  • The vaccine isn’t approved yet, however, and there will be challenges with producing it at a significant scale.

The market has been wildly excited about Moderna (NASDAQ:MRNA) this year, as it has soared more than 600% since January. The stock has been red hot on news that the cancer vaccine it has been working on with healthcare giant Merck has been shown to be highly effective in clinical trials.

Moderna’s market cap has swelled to close to $90 billion, up from less than $12 billion at the start of 2026. Is the company’s cancer vaccine truly a game changer for Moderna, or is hype and speculation fueling its returns this year?

Missed AI’s “Act 1”? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »

Image source: Getty Images.

The vaccine is highly effective, but investors may have gotten ahead of themselves

On Aug. 19, Moderna announced phase 3 clinical trial results that would send its stock skyrocketing. The results showed that its cancer vaccine, intismeran was highly effective in treating melanoma patients when paired with Keytruda, Merck’s top cancer drug. The combined treatment reduced the risk of death and of the cancer spreading or coming back, and was more effective than Keytruda on its own.

While approval hasn’t happened yet, it does appear highly likely. But there are multiple things to consider here. The stock’s mammoth price movement may appear to price in the potential for intismeran to treat other cancers as well, which is by no means a certainty. Plus, producing a personalized cancer vaccine at significant scale can be costly and time-consuming. And with the companies splitting the profits on the treatment, that will also diminish just how much profit may flow through to Moderna’s bottom line in the long run.

This is why, although the treatment is incredibly promising and could unlock significant growth potential for Moderna, many investors may have bid the stock up too aggressively, pushing its valuation to an unsustainable level.

Moderna’s inflated valuation makes the stock too risky to buy today

Intismeran has the potential to certainly be a game changer for Moderna, but it’s not there yet. It’s not approved to treat a single cancer, and the stock appears priced as if it’ll treat several.

The danger is that investors appear to be getting ahead of themselves and paying too much for the healthcare stock when there are still so many question marks about just how profitable intismeran will be, given the operational challenges that will come with producing a personalized cancer vaccine at scale.

I wouldn’t buy Moderna’s stock at its current price point, as it may be approaching a peak, if it hasn’t already hit one. The stock could have considerable downside risk at this point.

Should you buy stock in Moderna right now?

Before you buy stock in Moderna, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related reading

All Business →
AboutTermsPrivacyNewsInvestorsAdvisorsLogin
Dark mode